Naphthoquine: A Potent Broad-Spectrum Anti-Coronavirus Drug In Vitro |
| |
| Authors: | Yabin Song Yongqiang Deng Huiqiang Wang Zhuchun Bei Hongjing Gu Hui Zhao Hong Wang Dongna Zhang Likun Xu Baogang Wang Yuhuan Li Hongquan Wang |
| |
| Affiliation: | 1.State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, China; (Y.S.); (Y.D.); (Z.B.); (H.G.); (H.Z.); (H.W.); (D.Z.); (L.X.); (B.W.);2.CAMS Key Laboratory of Antiviral Drug Research, Beijing Key Laboratory of Antimicrobial Agents, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China; |
| |
| Abstract: | COVID-19 has spread around the world and caused serious public health and social problems. Although several vaccines have been authorized for emergency use, new effective antiviral drugs are still needed. Some repurposed drugs including Chloroquine, Hydroxychloroquine and Remdesivir were immediately used to treat COVID-19 after the pandemic. However, the therapeutic effects of these drugs have not been fully demonstrated in clinical studies. In this paper, we found an antimalarial drug, Naphthoquine, showed good broad-spectrum anti-coronavirus activity. Naphthoquineinhibited HCoV-229E, HCoV-OC43 and SARS-CoV-2 replication in vitro, with IC50 = 2.05 ± 1.44 μM, 5.83 ± 0.74 μM, and 2.01 ± 0.38 µM, respectively. Time-of-addition assay was also performed to explore at which stage Naphthoquine functions during SARS-CoV-2 replication. The results suggested that Naphthoquine may influence virus entry and post-entry replication. Considering the safety of Naphthoquine was even better than that of Chloroquine, we think Naphthoquine has the potential to be used as a broad-spectrum drug for coronavirus infection. |
| |
| Keywords: | coronavirus SARS-CoV-2 repurposing malaria Naphthoquine |
|
|
